Press Releases

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , May 16, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company focused on

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022 FDA Allows GEN-1 + Avastin Phase II study LAWRENCEVILLE, N.J. , May 10, 2022 (GLOBE NEWSWIRE) -- Celsion

LAWRENCEVILLE, N.J. , May 09, 2022 (GLOBE NEWSWIRE) -- Celsion   Corporation  (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible Platform Appears to Show Promise LAWRENCEVILLE, N.J. , April 21, 2022 (GLOBE NEWSWIRE) -- Celsion

  Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well   received at 2022 AACR A nnual M eeti ng LAWRENCEVILLE, N.J. , April 14, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) a clinical-stage company focused on DNA-based immunotherapy and

LAWRENCEVILLE, N.J. , April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine

LAWRENCEVILLE, NJ , April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, of 1,328,274 shares of common stock at a purchase

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J. , April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) a clinical-stage company

LAWRENCEVILLE, NJ , April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price

LAWRENCEVILLE, N.J. , April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings